From natural-product discovery to lead evaluation: Addressing the challenge of compound availability

The discovery of a bioactive natural product does not necessarily translate into a viable drug discovery program. Once biological activity has been identified, researchers need to establish what structural features drive that activity, determine how the compound behaves under experimental conditions, and obtain sufficient material to reproduce and extend the findings. For natural-product research, the availability and characterization of the compound can therefore become as important as its initial biological activity.

This challenge becomes particularly relevant when the compound is present at low abundance in its original biological source or when obtaining reproducible material requires complex extraction and purification. Without reliable access to the compound, downstream structure–activity relationship (SAR) studies, analytical characterization, and biological validation can be difficult to perform systematically.

Natural products provide chemical diversity — but also development complexity

Natural products have contributed substantially to modern pharmaceutical discovery. Newman and Cragg's analysis of drugs approved worldwide between January 1981 and September 2019 identified 185 small-molecule anticancer agents. Of these, 62 were classified as natural products or natural-product derivatives, accounting for 33.5%. When compounds incorporating natural-product structures or mimicking their pharmacophores were included, the proportion reached 64.9%.

The significance of these compounds is not simply that they originate in nature. Natural biosynthetic pathways generate stereochemically rich and structurally complex molecules, providing chemical scaffolds that can be difficult to reproduce through straightforward synthetic design. Such structures can provide starting points for investigating molecular interactions and identifying structural features associated with biological activity.

At the same time, structural complexity can introduce challenges for pharmaceutical research. A lead may contain multiple stereocenters, sensitive functional groups, or a complex molecular framework. Researchers therefore need to distinguish the activity of the intended compound from effects arising from impurities, degradation products, related analogues, or variations in the source material.

This makes chemical identity, purity, reproducibility, and material availability important considerations when moving from natural-product discovery to lead evaluation.

From bioactivity to structure–activity relationships

A positive screening result provides evidence of biological activity, but it does not by itself establish a structure–activity relationship.

SAR studies require researchers to compare related structures and determine which molecular features influence potency, selectivity, stability, or other properties of interest. For natural-product leads, this may involve studying the parent compound alongside naturally occurring analogues, derivatives, or structurally modified compounds.

The quality of this comparison depends partly on the availability of well-defined research materials. If the starting compound is difficult to obtain or its composition varies between batches, differences observed in biological assays may be harder to interpret.

This is one reason why the transition from natural-product identification to reproducible chemical research deserves attention in the early stages of drug discovery.

The supply question behind natural-product research

For some natural products, obtaining material directly from the original biological source is not a straightforward solution. The compound may occur at low concentrations, while extraction yield can depend on the source material and processing conditions. Large-scale extraction, chemical synthesis, semi-synthesis, or biotechnology-based production may therefore become potential strategies for increasing supply, depending on the compound.

These approaches serve different purposes. Extraction can preserve access to naturally occurring compounds but may require substantial biological material and downstream purification. Chemical synthesis or semi-synthesis can provide greater control over production but may be difficult for structurally complex molecules.

Biotechnology-based approaches can offer another route by leveraging biosynthetic pathways, engineered organisms, or enzymatic production.

For researchers at the discovery stage, however, the immediate requirement may be more straightforward: access to a defined compound in quantities suitable for laboratory investigation.

Biobased pharmaceutical chemicals as research materials

Biobased pharmaceutical chemicals provide one route for accessing naturally derived compounds without relying exclusively on direct collection or extraction from their original sources.

Alfa Chemistry provides a portfolio of biobased pharmaceutical chemicals originating from biological sources, including plants and microorganisms. Examples in the portfolio include piceatannol, naringin, salidroside, tetrahydropalmatine, and 7-epitaxol.

For pharmaceutical and biotechnology researchers, these compounds can serve as defined research materials for analytical characterization, natural-product chemistry, SAR investigations, and related studies. The portfolio is intended for research use only and does not represent an alternative to the full development and validation process required for pharmaceutical candidates.

Keeping promising leads moving

Natural-product drug discovery increasingly combines biological screening with analytical chemistry, metabolomics, genome mining, biosynthetic engineering, and computational approaches. These technologies can expand the ability to identify new compounds and understand their biological relevance, but they do not eliminate the practical need for accessible, well-characterized chemical materials.

The transition from ‘this molecule shows activity’ to ‘we understand why it is active and can investigate where it can lead’ requires reproducible chemistry alongside biological evidence.

For that reason, compound availability should be considered not merely a procurement issue, but part of the experimental infrastructure supporting natural-product drug discovery. Access to biobased pharmaceutical chemicals can help researchers maintain that connection between natural-product discovery, chemical characterization, SAR investigation, and the next stage of pharmaceutical research.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>